{
"@context": "https://schema.org",
"@graph": [
{
"@type": "WebPage",
"@id": "https://www.fortrea.com/insights/end-end-solutions-clinical-trials-device-and-post-approval-patient-safety-and#webpage",
"url": "https://www.fortrea.com/insights/end-end-solutions-clinical-trials-device-and-post-approval-patient-safety-and",
"name": "End-to-end solutions in clinical trials, device and post-approval patient safety and pharmacovigilance (PV) services",
"description": "This Fortrea info sheet highlights pharmacovigilance and patient safety services designed to support regulatory compliance, drug safety operations, and end-to-end safety management across clinical development and post-marketing programs. The publication discusses pharmacovigilance operations, regulatory intelligence pharmacovigilance strategies, patient safety monitoring activities, and operational approaches designed to strengthen compliance management within evolving global safety requirements. The publication also highlights operational challenges in compliance pharmacovigilance drug safety management, including maintaining safety oversight, monitoring reporting consistency, supporting regulatory readiness, and managing complex safety operations across clinical development activities. Fortrea supports sponsors through integrated pharmacovigilance and patient support services designed to strengthen patient safety management, improve operational continuity, and support end-to-end solutions in clinical trials and global drug safety programs. By integrating regulatory intelligence with pharmacovigilance operations and structured patient safety strategies, Fortrea supports more efficient safety oversight and continuity across global pharmacovigilance activities."
},
{
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "Home",
"item": "https://www.fortrea.com"
},
{
"@type": "ListItem",
"position": 2,
"name": "Insights",
"item": "https://www.fortrea.com/insights/"
},
{
"@type": "ListItem",
"position": 3,
"name": "End-to-end solutions in clinical trials, device and post-approval patient safety and pharmacovigilance (PV) services",
"item": "https://www.fortrea.com/insights/end-end-solutions-clinical-trials-device-and-post-approval-patient-safety-and"
}
]
},
{
"@type": "Organization",
"@id": "https://www.fortrea.com/#organization",
"name": "Fortrea",
"url": "https://www.fortrea.com",
"description": "Fortrea is a global contract research organization built on more than 30 years of experience and one of the earliest CRO legacies in the industry—as Covance, evolving within Labcorp, and now operating as Fortrea. With deep expertise across Phase I–IV clinical trials, Fortrea advances clinical research through a patient-centric approach that prioritizes meaningful outcomes, stronger site–CRO relationships, and operational excellence. Fortrea partners with biopharmaceutical, biotech, and medical device companies to advance therapies through every stage of clinical development. This commitment is further reinforced by the launch of Fortrea Intelligent Technology, enabling smarter, more connected, and data-driven clinical development. Through Fortrea Intelligent Technology, the organization is advancing data-driven, technology-enabled clinical development to improve speed, quality, and patient outcomes. It is shaped by experience, innovation, and a commitment to raising standards in clinical research—focused on accelerating development and helping bring life-changing treatments to patients around the world.",
"logo": "https://www.fortrea.com/sites/default/files/2025-05/fortrea-logo-without-background.png",
"sameAs": [
"https://www.linkedin.com/company/fortrea",
"https://www.threads.net/@fortreacro",
"https://twitter.com/fortrea",
"https://www.youtube.com/@Fortrea/",
"https://www.facebook.com/Fortrea-104143099267108",
"https://www.instagram.com/fortreacro"
]
},
{
"@type": "Article",
"@id": "https://www.fortrea.com/insights/end-end-solutions-clinical-trials-device-and-post-approval-patient-safety-and#infosheet",
"mainEntityOfPage": {
"@id": "https://www.fortrea.com/insights/end-end-solutions-clinical-trials-device-and-post-approval-patient-safety-and#webpage"
},
"headline": "Managing Pharmacovigilance and Patient Safety Through End-to-End Safety Services | Fortrea Info Sheet",
"description": "This Fortrea info sheet highlights pharmacovigilance and patient safety services designed to support regulatory compliance, drug safety operations, and end-to-end safety management across clinical development and post-marketing programs. The publication discusses pharmacovigilance operations, regulatory intelligence pharmacovigilance strategies, patient safety monitoring activities, and operational approaches designed to strengthen compliance management within evolving global safety requirements. The publication also highlights operational challenges in compliance pharmacovigilance drug safety management, including maintaining safety oversight, monitoring reporting consistency, supporting regulatory readiness, and managing complex safety operations across clinical development activities. Fortrea supports sponsors through integrated pharmacovigilance and patient support services designed to strengthen patient safety management, improve operational continuity, and support end-to-end solutions in clinical trials and global drug safety programs. By integrating regulatory intelligence with pharmacovigilance operations and structured patient safety strategies, Fortrea supports more efficient safety oversight and continuity across global pharmacovigilance activities.",
"genre": "Info Sheet",
"image": {
"@type": "ImageObject",
"url": "https://www.fortrea.com/sites/default/files/2025-10/end-to-end-patient-safety-and-pharmacovigilance-services.jpg"
},
"author": {
"@type": "Organization",
"name": "Fortrea",
"url": "https://www.fortrea.com/"
},
"publisher": {
"@id": "https://www.fortrea.com/#organization"
},
"datePublished": "2025-10-16",
"dateModified": "2025-10-16",
"encoding": {
"@type": "MediaObject",
"contentUrl": "https://www.fortrea.com/sites/default/files/2025-10/end-to-end-patient-safety-and-pharmacovigilance-services.pdf",
"encodingFormat": "application/pdf"
}
}
]
}